Angiomyolipoma medical therapy: Difference between revisions
| Line 14: | Line 14: | ||
==Medical Therapy== | ==Medical Therapy== | ||
[[Everolimus]], an m TOR inhibitor, is FDA approved for the treatment of Angiomyolipomas.It is most commonly used in tuberous sclerosis associated Angiomyolipoma rather than sporadic cases. It has been shown to reduce the tumor volume as well as its risk of progression. | [[Everolimus]], an m TOR inhibitor, is FDA approved for the treatment of Angiomyolipomas.It is most commonly used in tuberous sclerosis associated Angiomyolipoma rather than sporadic cases. It has been shown to reduce the tumor volume as well as its risk of progression.<ref name="pmid24729041">{{cite journal| author=Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM et al.| title=The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. | journal=Nephrol Dial Transplant | year= 2014 | volume= 29 | issue= 6 | pages= 1203-10 | pmid=24729041 | doi=10.1093/ndt/gfu013 | pmc=4852219 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24729041 }}</ref> | ||
=== Indications of Everolimus in Angiomyolipoma: === | === Indications of Everolimus in Angiomyolipoma: === | ||
Revision as of 08:17, 1 August 2018
|
Angiomyolipoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiomyolipoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Angiomyolipoma medical therapy |
|
Risk calculators and risk factors for Angiomyolipoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Treatment options include selective renal artery embolization,nephron sparing surgery( enucleation or partial nephrectomy), complete and radical nephrectomy, radio-frequency ablation and everolimus. Angiomyolipomas found incidentally,asymptomatic, < 4 cm in size, generally requires no intervention beside periodic evaluation.Medium sized lesion(4-8 cm) should be closely followed with the serial imaging studies(every 6 month and then yearly once stable) and elective intervention provided if the change in the size or symptoms noticed to increases the chances of renal function salvage..Larger lesion(>8cm), shown to progress to the development of the complication so treated elective.[1]
Treatment and management of the Angiomyolipoma depends largely on
- size of the tumors,
- signs and symptoms,
- presence or absence of Life threatening hemorrhage,
- its association with the tuberous sclerosis and the presence of the comorbities.[2]
Medical Therapy
Everolimus, an m TOR inhibitor, is FDA approved for the treatment of Angiomyolipomas.It is most commonly used in tuberous sclerosis associated Angiomyolipoma rather than sporadic cases. It has been shown to reduce the tumor volume as well as its risk of progression.[3]
Indications of Everolimus in Angiomyolipoma:
- Multiple large Angiomyolipoma
- Bilateral Angiomyolipoma
- Progression of the lesion( > 5mm/year)
- Hx of prior nephrectomy or emblolization
Patients with loss of renal function should be monitored for:
- Hypertension
- Adverse effects of nephrotoxic drugs such as:
- NSAIDS
- IV contrast agents
References
- ↑ Dickinson M, Ruckle H, Beaghler M, Hadley HR (1998). "Renal angiomyolipoma: optimal treatment based on size and symptoms". Clin Nephrol. 49 (5): 281–6. PMID 9617489.
- ↑ Oesterling JE, Fishman EK, Goldman SM, Marshall FF (1986). "The management of renal angiomyolipoma". J Urol. 135 (6): 1121–4. PMID 3520013.
- ↑ Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM; et al. (2014). "The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1". Nephrol Dial Transplant. 29 (6): 1203–10. doi:10.1093/ndt/gfu013. PMC 4852219. PMID 24729041.